A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen.

BACKGROUND

There have been conflicting data in literature about the value of Phyllanthus amarus in treating hepatitis B virus-related disorders.

OBJECTIVE

To evaluate the role of Phyllanthus amarus in eradication of the virus in hepatitis B carriers.

METHODS

Phyllanthus amarus was administered to 30 asymptomatic carriers of hepatitis B surface antigen (HBsAg) in a dosage of 250 to 500 mg thrice daily for 4 to 8 weeks.

RESULTS

None of the 30 subjects cleared HBsAg. Phyllanthus amarus was well tolerated, with no clinical side effects or changes in the organ profiles for safety evaluation.

CONCLUSIONS

Phyllanthus amarus is not effective in clearing HBsAg in asymptomatic carriers of the antigen.